期刊文献+

中西医结合治疗癌性骨痛的临床疗效观察 被引量:9

Clinical Observation of Treating Cancerous Ostalgia with Integrated Traditional Chinese and Western Medicine
原文传递
导出
摘要 目的:评价中西医结合治疗癌性骨痛的临床疗效和安全性。方法:将68例恶性肿瘤骨转移伴有疼痛患者随机分为对照组和治疗组。对照组32例,给予双膦酸盐类药物治疗,1次/28d,用药2次;治疗组36例,在上述基础上给予中药愈骨汤口服以及膏药贴贴舒外敷,用药2个周期。观察两组患者用药后临床获益率、止痛起效时间和持续时间及骨扫描的变化;治疗不良反应方面观察患者体温、骨痛、下颌痛、血钙及肾功能的变化。结果:①止痛临床获益率比较,治疗组为94.4%,对照组为65.6%,差异有统计学意义(P<0.05)。止痛起效时间和可持续时间比较,治疗组优于对照组,差异有统计学意义(P<0.05)。②用药后治疗组1例出现骨痛、肌痛加重,对照组2例出现骨痛、肌痛加重,考虑与骨质严重损害及唑来膦酸的作用有关,改用帕米磷酸二钠继续治疗后缓解。治疗组发热2例,对照组发热1例,给予对症治疗后缓解。两组患者治疗前后血钙及肾功能等未见明显变化。结论:中西医结合治疗癌性骨痛起效快,持续时间长,毒副反应轻,有较好的临床应用前景。 Objective: To investigate the clinical benefit and safety of treating cancerous ostalgia with integrated traditional Chinese and western medicine.Methods: A total of 68 cases of malignant tumors accompanied by painful bone metastases were randomly divided into control group and treatment group:the 32 cases in control group were treated with biphosphonates per 28 days for two times;the 36 cases in treatment group were given the Chinese herbal medicine both orally and externally besides the same treatment of control group for two periods.The clinical benefit rate,onset time,duration and the changing of bone scanning of the two groups were observed.Meanwhile,the temperature,bone pain,mandible joints pain,the change of serum calcium density and kidney function were detected to observe the side effects of the treatment.Results: ①The clinical benefit rates in treatment group and control group were 94.4% and 65.6% respectively and the difference was significant(P0.05).The onset time and duration of treatment group were better than those of control group significantly(P0.05).② After the treatment there were 1 case in treatment group and 2 cases in control group suffering from increased pain in bone and muscle,which may be caused by the serious damage of the bone and the effect of zoledronic acid.This situation was improved after we changed the zoledronic acid with pamidronate disodium.There were 2 cases of high temperture in treatment group,while,there were 1 case of high temoperature in control group,and they all taken a favorable turn after heteropathing.No significant change in blood calcium and renal functions were observed in both two groups.Conclusion: The treatment of cancerous ostalgia with integrated Chinese and western medicine can relive the pain quickly and lastingly with little side effects,thus enjoying good prospects for clinical application.
出处 《上海中医药大学学报》 CAS 2010年第2期28-30,共3页 Academic Journal of Shanghai University of Traditional Chinese Medicine
基金 国家自然科学基金资助项目(30860361)
关键词 癌性骨痛 双磷酸盐类药物 中医药疗法 Cancerous ostalgia bisphosphonates traditional Chinese medicine
  • 相关文献

参考文献5

二级参考文献50

  • 1刘瑶,刘治军,傅得兴.新一代二膦酸盐类药物唑来膦酸的药理及临床[J].中国新药杂志,2004,13(11):1058-1060. 被引量:11
  • 2杨文,唐武兵,古伟光,伍楚蓉,罗海涛,张复华.唑来膦酸治疗恶性肿瘤骨转移引起疼痛的疗效分析[J].中华肿瘤防治杂志,2006,13(12):949-950. 被引量:12
  • 3[1]Bukowski JF,Dascher CC,Das H.Alternative bisphosphonate targets and mechanisms of action.Biochem Biophys Res Commun,2005,328:746 被引量:1
  • 4[2]Ferretti G,Fabi A,Carlini P,et al.Zoledronic -acidinduced circulating level modifications of angiogenic factors,metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.Oncology,2005,69:35 被引量:1
  • 5[3]Clézardin P,Ebetino FH,Fournier PG.Bisphosphonates and cancer-induced bone disease:Beyond their antiresorptive activity.Cancer Res,2005,65:4971 被引量:1
  • 6[4]Pavlakis N,Stockler M.Bisphosphonates for breast cancer.Cochrane Database Syst Rew,2005,CD003474. 被引量:1
  • 7[5]Tripathy D,Lichinitzer M,Lazarev A,et al.Oral ibandronate for the treatment of metastatic bone disease in breast cancer:Efficacy and safety results from a randomized,double-blind,placebo-controlled trial.Ann Oncol,2004,15:743 被引量:1
  • 8[6]Body JJ,Diel IJ,Bell R,et al.Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.Pain,2004,111:306 被引量:1
  • 9[7]Heidenreich A,Ohlmann C,Body JJ.Ibandronate in metastatic bone pain.Semin Oncol,2004,31:67 被引量:1
  • 10[8]Pecherstorfer M.Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.Expert Opin Pharmacother,2004,5:2341 被引量:1

共引文献61

同被引文献158

引证文献9

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部